Previous 10 | Next 10 |
Are Biotech Penny Stocks On Your Watch List This Week? Penny stocks are well known for their volatility swings. Whether we’re talking about stocks with insider trading, meme stocks, or penny stocks with high analyst ratings, there are myriad catalysts to seek out. However, sp...
LOS ANGELES, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Linda Mar...
LOS ANGELES, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention o...
ContextLogic (NASDAQ:WISH) -27% on Q2 earnings release Cricut (NASDAQ:CRCT) -22% on Q2 earnings release Rigel Pharmaceuticals (NASDAQ:RIGL) -18% after FDA declines to approve fostamatinib COVID-19 EUA LifeMD (NASDAQ:LFMD) -13% on Q2 earnings release Sie...
Capricor Therapeutics, Inc. (CAPR) Q2 2021 Earnings Conference Call August 12, 2021 16:30 ET Company Participants AJ Bergmann - Chief Financial Officer Linda Marbán - Chief Executive Officer Conference Call Participants Emanuela Branchetti - H.C. Wainwright Alan Leong - BioWatch News Pre...
CAP-1002 – Capricor’s Cell Therapy Program for Duchenne Muscular Dystrophy -Phase III Trial Protocol Submitted to FDA Following FDA Guidance- -Commencing Start-Up Activities for Pivotal Trial- -Phase II, HOPE-2 Final Data Submitted for Publication- CAP-10...
LOS ANGELES, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial resu...
-Preclinical Data Demonstrates Capricor’s Exosome Product as an Antishock Therapeutic if Delivered Early -Publication Further Supports Capricor’s Exosome Platform Advancement- LOS ANGELES, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Cap...
LOS ANGELES, July 27, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of...
Marin Software Incorporated (MRIN) +63% on new InstaCart Ad Integration.India Globalization Capital (IGC) +22% on Alzheimer’s drug trial update.GTT Communications (GTT) +21%.Aravive, Inc. (ARAV) +20% on early-stage kidney cancer study data.Arcus Biosciences (RCUS) +19%...
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000 ® Index an...
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment- -Pre-BLA Meeting with FDA...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with FDA for Deramiocel" were omitted ...